Glucagon-Like Peptide-1 Agonist Use for Obesity Treatment in Patients with Left Ventricular Assist Devices

Purpose: A BMI>35 kg/m2 is a relative contraindication for heart transplantation (HT) at many centers. Glucagon-like peptide-1 agonists (GLP-1a) are an effective weight loss treatment for patients with obesity. Whether GLP-1induces weight loss in obese patients with left ventricular assist devices (LVAD) and increases medical candidacy for HT is unknown.

Source: The Journal of Heart and Lung Transplantation - April 1, 2024 Category: Transplant Surgery Authors: , M. Thomas, D. Varghese, L. Truby, C. Wrobel, E. Hardin, J. Thibodeau, M. Drazner, M. Peltz, M. Farr, J. Grodin, N. Hendren Source Type: research